@article{d4f406bae9e6499ea35521ac1d64924a,
title = "Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion",
keywords = "Anti-CD20 monoclonal antibody, Efficacy, Mechanisms of action, Multiple sclerosis, Progressive multiple sclerosis, Relapsing multiple sclerosis, Safety, Treatment",
author = "Afsaneh Shirani and Olaf Stuve and Cross, {Anne H.}",
note = "Funding Information: A. Shirani has no disclosures to report. O. Stuve serves on the editorial boards of Therapeutic Advances in Neurological Disorders, has served on data monitoring committees for Genentech-Roche, Pfizer, Novartis, and TG Therapeutics without monetary compensation, has advised EMD Serono and VYNE, receives grant support from EMD Serono , is a 2021 recipient of a Grant for Multiple Sclerosis Innovation (GMSI), Merck KGaA, is funded by a Merit Review grant federal award document number (FAIN) BX005664-01 from the United States (U.S.) Department of Veterans Affairs, Biomedical Laboratory Research and Development , is funded by RFA-2203-39314 (PI) and RFA-2203-39305 (co-PI) grants from the National Multiple Sclerosis Society, United States (NMSS). A.H. Cross was supported in part by the Manny & Rosalyn Rosenthal —Dr John L. Trotter Chair in Neuroimmunology. A.H. Cross has received honoraria for consulting or serving on scientific advisory boards from Biogen, Bristol Myers Squibb, EMD Serono, United States, Genentech, Horizon, Janssen (J&J), Novartis, Octave, Roche, Switzerland, and TG Therapeutics. A.H. Cross has received contracted grants from Genentech, United States , EMD Serono, and Roche .",
year = "2024",
month = feb,
doi = "10.1016/j.ncl.2023.06.001",
language = "English (US)",
volume = "42",
pages = "137--153",
journal = "Neurologic Clinics",
issn = "0733-8619",
publisher = "W.B. Saunders Ltd",
number = "1",
}